Form D · Pharmaceuticals
Cingulate Inc.
Kansas City, KS · CIK 0001862150
Offering snapshot reported Sep 28, 2021 · SEC filing
- Reported sold
- Yet to sell Offering amount: $220M
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 28, 2021 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-414866
Implied per share value. Stock exchange in connection with restructuring merger.
Source: Form D, filed Sep 28, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jeff Conroy | Director |
| Patrick Gallagher | Director |
| Gregg Givens | Director |
| Jeff Hargroves | Director |
| Curt Medeiros | Director |
| Shane J Schaffer | Director, Executive |
| Peter J Werth | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1901 W. 47 Th Place
Kansas City, KS, 66205
Kansas City, KS, 66205